Allos Therapeutics to Present at Upcoming Investor Conferences
September 13 2010 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present at the following
investor conferences during the month of September.
September 21, 2010 UBS Global Life Sciences Conference The Grand
Hyatt, New York City 4:30 p.m. ET September 27, 2010 JMP
Securities Healthcare Conference New York Palace Hotel, New York
City 9:30 a.m. ET
Attendance at these conferences is by invitation only. A live
audio webcast of select presentations can be accessed from and
available for replay through a link on the home page and investor
relations section of the Allos corporate website.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other hematologic malignancies
and solid tumors. Allos retains exclusive worldwide rights to
FOLOTYN for all indications. Allos is headquartered in Westminster,
CO. For additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will
contain forward-looking statements that involve significant risks
and uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2010 and in the Company's other periodic
reports and filings with the Securities and Exchange Commission.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. All
forward-looking statements are based on information currently
available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
these presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024